Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?
| Autor: | Maria Blettner, Rolf Kreienberg, Catharina Bartmann, Mathias Krockenberger, Achim Wöckel, J Diessner, Sebastian Häusler, Tanja Stüber, I. Novopashenny, Manfred Wischnewsky, Roland Stein, Wolfgang Janni |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Antineoplastic Agents Breast Neoplasms urologic and male genital diseases Risk Assessment digestive system Systemic therapy Drug Administration Schedule Young Adult 03 medical and health sciences 0302 clinical medicine Breast cancer Germany Internal medicine medicine Carcinoma Humans Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Aged 80 and over Chemotherapy business.industry General Medicine Small tumours Middle Aged Prognosis medicine.disease female genital diseases and pregnancy complications Node negative body regions 030104 developmental biology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Practice Guidelines as Topic Female business Adjuvant Tamoxifen medicine.drug |
| Zdroj: | Oncology. 92:317-324 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Objective: To identify subgroups of patients with pT1 pN0 breast cancer (BC) who might not profit from adjuvant systemic therapy (AST). Methods: Data of 3,774 pT1 pN0 BC patients from 17 certified BC centres within the BRENDA study group were collected between 1992 and 2008 and retrospectively analysed. Uni- and multivariate analyses were performed using Kaplan-Meier methods and Cox regression models. Results: 279 (7.4%) of the pT1 pN0 BC patients were T1a, 944 (25.0%) were T1b and 2,551 (67.6%) were T1c. There was no significant difference (p > 0.1) in recurrence-free survival (RFS)/overall survival (OAS) between patients with pT1a, pT1b, and T1c. Patients receiving any type of AST had a better outcome compared to women without AST after adjusting for age, tumour size, and intrinsic subtypes (RFS: p < 0.001; OAS: p < 0.001). AST was the most important prognostic parameter for RFS followed by intrinsic subtypes and age. Conclusion: Patients with pT1 pN0 BC profit from AST independently of molecular subtypes, tumour size, age or comorbidity, with 5-year RFS of more than 95%. The correct definition of subgroups of patients who do not need AST is still an open question. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|